摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-iodo-2-ethoxy-3-methoxypyridine | 1044671-47-7

中文名称
——
中文别名
——
英文名称
6-iodo-2-ethoxy-3-methoxypyridine
英文别名
2-Ethoxy-6-iodo-3-methoxypyridine
6-iodo-2-ethoxy-3-methoxypyridine化学式
CAS
1044671-47-7
化学式
C8H10INO2
mdl
——
分子量
279.077
InChiKey
ZKMSUVJZZVVQJX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    290.4±40.0 °C(Predicted)
  • 密度:
    1.648±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    12
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    31.4
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] PYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DE RÉCEPTEURS D'OREXINE AU PYRIDINECARBOXAMIDE
    申请人:MERCK & CO INC
    公开号:WO2009020642A1
    公开(公告)日:2009-02-12
    The present invention is directed to pyridyl carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    本发明涉及吡啶基羧酰胺化合物,这些化合物是促进睡眠的受体拮抗剂,可用于治疗或预防涉及促进睡眠的神经和精神障碍和疾病。该发明还涉及包含这些化合物的药物组合物,以及在预防或治疗涉及促进睡眠的这类疾病中使用这些化合物和组合物。
  • TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS
    申请人:Coleman Paul J.
    公开号:US20100035931A1
    公开(公告)日:2010-02-11
    The present invention is directed to tripyridyl carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
    本发明涉及三吡啶基羧酰胺化合物,它们是促进睡眠的受体拮抗剂,可用于治疗或预防涉及促进睡眠的神经和精神障碍和疾病。该发明还涉及包含这些化合物的药物组合物,以及在预防或治疗涉及促进睡眠的这类疾病中使用这些化合物和组合物。
  • Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs
    申请人:Schumacher Richard
    公开号:US20050222207A1
    公开(公告)日:2005-10-06
    PDE4 inhibition is achieved by novel compounds, e.g., N-substituted diarylamine analogs. The compounds of the present invention are of Formula I: wherein A, B, D, R 1 , R 2 , R 3 and R 4 are as defined herein.
    PDE4抑制是通过新型化合物实现的,例如N-取代二芳胺类似物。本发明的化合物为I式:其中A、B、D、R1、R2、R3和R4如本文所定义。
  • PHOSPHODIESTERASE 4 INHIBITORS
    申请人:Talamas Francisco Xavier
    公开号:US20090118270A1
    公开(公告)日:2009-05-07
    PDE4 inhibition is achieved by novel compounds, e.g., N-substituted diarylamine analogs. The compounds of the present invention are of Formulas I-III: wherein A, B, D, E, G, J, K, R 1 , R 2 , R 3 , R 4 , R 11 , R 12 , R 13 , R 14 , R 21 , R 22 , R 23 and R 24 are as defined herein.
    PDE4抑制作用是由新型化合物实现的,例如N-取代的二芳胺类似物。本发明的化合物属于I-III式,其中A、B、D、E、G、J、K、R1、R2、R3、R4、R11、R12、R13、R14、R21、R22、R23和R24如本文所定义。
  • Phosphodiesterase 4 inhibitors
    申请人:Talamas Xavier Francisco
    公开号:US20070049611A1
    公开(公告)日:2007-03-01
    PDE4 inhibition is achieved by novel compounds, e.g., N-substituted diarylamine analogs. The compounds of the present invention are of Formulas I-III: wherein A, B, D, E, G, J, K, R 1 , R 2 , R 3 , R 4 , R 11 , R 12 , R 13 , R 14 , R 21 , R 22 , R 23 and R 24 are as defined herein.
    PDE4抑制作用是通过新型化合物实现的,例如N-取代二芳胺类似物。本发明的化合物属于I-III式:其中A、B、D、E、G、J、K、R1、R2、R3、R4、R11、R12、R13、R14、R21、R22、R23和R24如本文所定义。
查看更多